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(57) ABSTRACT 
A method and kit for detection of Mycobacterium Avium 
Subspecies Paratuberculosis (MAP) in blood and blood 
derivative samples from humans by culture and PCR. Tech-
nology can screen for MAP in blood samples from millions of 
patients having inflammatory and non-inflammatory bowel 
diseases, and the results are used to identify those patients 
with MAP for treatment by antibiotics. The method and kit 
can monitor and evaluate the outcome of therapy. 
18 Claims, 7 Drawing Sheets 
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Sequence ID 1 P90 5-GITCGGGGCCGTCGCTI AGG-3 
Figure 1 
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Sequence ID 2 P91 5-GAGGTCGATCGCCCACGTGA-3 
Figure 2 
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Sequence ID 3 AVI 5-ATGTGGTIGCTGTGTTGGATGG-3 
Figure 3 
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Sequence ID 4 A V2 5-CCGCCGCAA TCAACTCCAG-3 
Figure 4 
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Figure 6A 
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1 
PROTOCOL FOR DETECTION OF 
MYCOBACTERIUM AV/UM SUBSPECIES 
PARATUBERCULOS/S IN BLOOD 
This invention claims the benefit of priority from U.S. 5 
Provisional Patent Application Ser. No. 60/660,417 filed Mar. 
10, 2005. 
FIELD OF THE INVENTION 
2 
may be other etiologies for Crohns or irritable bowel syn-
drome other than MAP) using a simple blood test. This blood 
test can also be used to identify Crohn' s disease patient popu-
lation with MAP infection. Additonally, this novel blood test 
can be used to differentiate IBD patients with MAP infection 
from those without MAP infection. Moreover, such tests can 
be used to monitor and evaluate treatment after obtaining a 
first positive result. Repeat blood tests can determine if the 
bacterium is being reduced or eliminated from the system, or 
10 not. 
This invention relates to the detection of the bacterium 
Mycobacterium Avium Subspecies Paratuberculosis (MAP), 
and in particular to a method and kit for using blood via PCR 
and culture to detect patients having the bacterium and ulti-
mately to select those patients having the bacterium for treat- 15 
ments. 
BACKGROUND AND PRIOR ART 
SUMMARY OF THE INVENTION 
A primary objective of the present invention is to provide 
for using blood via PCR and culture to detect MAP. 
A second objective of the invention is to provide a method 
to diagnose those patients with Crohn' s disease or ulcerative 
colitis caused by the bacterium. 
A third objective of the invention is to ultimately select 
20 those persons who would benefit by anti-MAP treatment. Inflammatory bowel diseases, such as Crohn's disease or 
ulcerative colitis cause inflammation of the gastrointestinal 
tract, most commonly the small intestine, with resulting 
abdominal pain, difficulty in digesting food, and other symp-
toms. Clinically diagnosing Crohn's or ulcerative colitis is an 
expensive, time consuming process which often requires 25 
some form of anesthesia. Generally, such diagnosis is made 
by performing an endoscopy, colonscopy, sigmoidoscopy or 
radiological technique which often must be done in a hospital 
or clinic-like setting and sometimes requiring a biopsy of 
apparently affected tissue. It is estimated that at least one 
million Americans have Inflammatory Bowel Disease (IBD), 
with about 50% having Crohn's disease and about 50% hav-
ing ulcerative colitis. Because of health care costs and diag-
nostics, the actual estimated number of patients with IBD 
may be significantly higher. Therefore it would be highly 
desirable to have a diagnostic test that is less invasive, less 
expensive and can accurately identify those patients with 
MAP infection. Ultimately, treatment with appropriate anti-
biotics will go a long way toward relieving them from the 
disease. 
Based on the clinical similarities of animals infected with 
paratuberculosis, early research suggested that the disease 
which came to be known as Crohn's disease was caused by 
mycobacteria Early studies on Crohn' s disease did not detect 
MAP in tissues from patients with Crohn's disease by con-
ventional staining and culture techniques because such 
patients may have mycobacterium which are cell-wall defi-
cient, and because of the difficulties in cultivating MAP, with 
A method is provided for monitoring and evaluating the 
course of irritable bowel disease by determining the presence 
or absence of irritable bowel disease caused by MAP after the 
initial diagnosis, and through treatment. 
A preferred method of diagnosing inflanimatory bowel 
disease in those patients who have bowel disease caused by 
Mycobacterium Avium Paratuberculosis (MAP) using a 
sample of peripheral blood tissue includes selecting a blood 
sample from at least a single patient of selected patients, 
30 culturing that blood sample for a period of time sufficient to 
obtain a sufficient growth of MAP to subject to PCR, and 
detecting MAP therefrom. 
The preferred method is used when the patient is a human 
patient having inflammatory bowel disease which is known as 
35 Crohn's disease, irritable bowel disease (IBD), or Ulcerative 
colitis. A more preferred method further includes treating 
MAP infected patients who have MAP detected in their blood 
with an anti-MAP effective amount of an anti-MAP com-
pound and a pharmaceutically acceptable excipient therefor. 
40 A preferred method of treating MAP infected patients 
includes using an anti-MAP compound that is an antibiotic in 
an effective amount is an amount sufficient to eliminate MAP 
from registering positive in a blood test. 
The preferred method of treating MAP infected patients 
45 includes a time required to culture the blood sample of from 
approximately 8 weeks to approximately 12 weeks, prefer-
ably 12 weeks. The blood sample is cultured in media selec-
tive for MAP that includes Mycobacterial Growth Indicator 
Tube (MGIT), BACTEC or BACTEC further supplemented its slow growing characteristics. A research group at Baylor 
College of Medicine patented the discovery of p36 (a protein 
from MAP) for serologic detection of MAP antibodies from 
Crohn's patients in U.S. Pat. No. 5,776,699. Researchers 
have also recently utilized the insertion element IS 900 to 
accurately identify MAP (Mishina, D Katsel, P Brown, S t 
Gilberts, E C Greenstein R J "On the Etiology of Crohn 55 
Disease" Proc Natl Acad Sci USA 1996, 93: 9816-20.) and 
others have found MAP in tissue and breast milk samples 
from lactating mothers with Crohn's disease (D. Schwartz et 
al., "Use of short-term culture for identification of Myca bac-
terium avium subsp paratuberculosis in tissue from Crohn's 60 
disease patients" Clin Microbial Infect 2000: 6, 303-307. 
Naser, SA Schwartz, D. Shafran, I, "Isolation of Mycobac-
terium avium subsp paratuberculoisis from breast milk of 
Crohn's disease patients" Am Jl Gastroenterol 2000, 
95:1094-5. 
50 with 1 % sucrose. 
The preferred method of treating MAP infected patients 
further includes the use of the PCR method to detect MAP 
using one of more of the group consisting of Seq ID 1, Seq 
ID2, Seq ID 3 and Seq ID 4 as primers for nested PCR or the 
method can include the use of. primers that include one or 
more of the group consisting of Seq ID 1, Seq ID 2, Seq ID 3 
and Seq ID 4 and nucleotide polymorphisms thereof. 
It is also within the present invention to use one or more of 
Seq ID 1 or Seq ID 2 as primers in the first round of PCR and 
one or more of Seq ID 3 or Seq ID 4 in the second round of 
PCR. 
The present invention also includes a preferred method for 
monitoring and evaluating the course of inflanimatory bowel 
disease caused by MAP that includes selecting a blood 
65 sample from at least a single patient of selected patients, 
culturing that blood sample for a period of time sufficient to 
obtain a sufficient growth of MAP to subject to PCR, detect-
At the present time, however, no one has provided a method 
for diagnosing Crohn's disease that is caused by MAP (there 
US 7,488,580 Bl 
3 
ing MAP therefrom, obtaining a positive result for MAP, and 
continuing to repeat said test at intervals throughout treat-
ment. 
The method for treatment of the inflammatory bowel dis-
ease known as Crohn's disease requires a volume of blood 5 
extracted from the patient for use in the test in an amount of 
approximately 4 mis or greater. 
A preferred kit for use in diagnosing inflammatory bowel 
disease caused by Mycobacterium Avium Paratuberculosis 
(MAP) in blood includes primers, Seq ID 1, Seq ID2, Seq ID3 10 
and SeqID4. 
4 
4 in FIG. 4) oligonucleotide primers in the second round to 
re-amplify an 298 base pair internal nucleotide sequence for 
the 398 base pair template as shown in FIG. 5. In FIG. 5, 
positive results are indicated by a bright 298 bp band (arrow) 
on 2% agarose gel electrophoresis. M=molecular weight 
marker. Lane 1 represents DNA from MAP strain ATTC 
43015 as a positive control ( + ); lanes A2 and B2 represent 
negative controls for second round of nested PCR, lanes A3 
and A4 represent negative controls for first round of nested 
PCR and for DNA extraction steps, respectively. Positive and 
negative controls were run along with each sample analysis. 
For the composite image shown in FIG. 5, only representative 
positive and negative controls are shown. FIG. 5 results are 
shown for Crohn's Disease Patients, Ulcerative colitis (UC) 
Further objects and advantages of this invention will be 
apparent from the following detailed description of the pres-
ently preferred embodiments which are illustrated schemati-
cally in the accompanying drawings. 15 Patients and Patients with No Inflanimatory Bowel Disease 
(Non-IBD). 
BRIEF DESCRIPTION OF THE FIGURES The PCR conditions consisted of a reaction medium of 
5-mM MgCl2, 0.2 mM dNTP, 6% DMSO or 0.5M Betaine, 2 
micromolar primers and 2.5 units of Platinum Taq poly-FIG. 1 is Seq ID l-P90 primer 
FIG. 2 is Seq ID 2-P91 Primer 
FIG. 3 is Seq ID 3-AVl Primer 
FIG. 4 is Seq ID 4-AV2 Primer 
FIG. 5 is an autoradiograph of Nested PCR detection of 
MAP DNA from cultured peripheral blood samples 
FIG. 6A is a drawing of microscopic MAP cultures isolated 
from blood (5 week old MGIT culture from patient with 
Crohn's disease) 
20 merase purchased from Invitrogen, Calsbad Calif. or 1 unit of 
TFL DNA polymerase purchased from Promega, Madison, 
Wi. and 10 microliters of DNA template. The PCR reaction 
mixture in the second round of the nested PCR was the same, 
except that 5 microliters of PCR product from the first round 
FIG. 6B is a representative acid-fast positive MAP culture 
from a patient with Crohn's disease after 12 weeks of incu-
bation. 
25 was used as a template and the AV! andAV2 oligonucleotide 
primers were substituted. The PCR cycling conditions were 
95 degrees C. for 5 min, 34 cycles of95 degrees for 1 minute 
and 58 degrees C. for 1.5 minutes, 72 degrees C. for 1.5 
minutes and a final extension of 10 minutes at 72 degrees C. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
30 The amplification product size was assessed on 2% agarose 
gel, however one can also use real time PCR using the above 
condition where agarose gel may not be needed for reading 
the results. The same protocol may be applied using quanti-
Before explaining the disclosed embodiments of the 35 
present invention in detail it is to be understood that the 
invention is not limited in its applications to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 40 
Blood samples were taken from patients, and drawn into 
sterile K2-EDTA vacutainer tubes. A sample of each buffy 
coat (the middle layer of blood products) were used to inocu-
late into media that is selective for Mycobacterium avian 
subsp paratuberculosis (MAP). Such media may be Myca- 45 
bacterial Growth Indicator Tubes (MGIT) or MGITpara (pur-
chased from Becton Dickinson, Franklin Lake, N.J.) or 
BACTEC (purchased from Beckton Dickinson, Franklin 
Lake, N.J.) or other selective media and added to 4 ml of 
modified Middlebrook 7H9 broth base. The media is opti- 50 
mally supplemented with 0.1 % sucrose, MycobactinJ (Allied 
Monitor) and PANTA (Becton Dickinson, Franklin Lake, 
N.J.) as described in Schwartz, D, Schafran, I, Romero, C, et 
al. "Use of short-term culture for identification of Mycobac-
terium avium subsp paratuberculosis in tissue from Crohn's 55 
disease patients." Clin Microbial Infect 2000, 6: 303-307. 
MAP requires long term culturing, and the cultures were 
incubated for 8-12 weeks. 
tative real time PCR. 
Once positive tests are obtained using this method, patients 
can be treated using anti-MAP compounds. Such compounds 
may be antibiotics. Antibiotics with known specificities for 
MAP are Clarithromycin, Rifabutin and Clofazimine. 
Example 1 
Patients and Samples: 52 participants were included in the 
study: 28 with Crohn's disease, nine with ulcerative colitis 
and 15 without inflanimatory bowel disease (two with colon 
cancer, one with diverticulitis, one with gastrooesophageal 
reflux and 11 healthy individuals). Informed consent was 
obtained in accordance with institutional review board regu-
lations at the University of Florida, Gainesville Veterans 
Affairs Medical Center, and the University of Central Florida. 
Of the patients with Crohn's disease, 22 of28 (78%) and all 
the patients with ulcerative colitis were recruited from the 
inflammatory bowel disease clinic at the University of 
Florida, a tertiary referral centre. The diagnosis of Crohn's 
disease or ulcerative colitis was established on standard clini-
cal, endoscopic, histological, and radiographic criteria. Dis-
ease activity was assessed by use of the Harvey Bradshaw 
index or the clinical findings of the treating physician. Only 
one of the patients with Crohn's disease, and none of those Cultures were assessed for the presence of MAP by stain-
ing and then subjecting to nested PCR. Genomic DNA was 
extracted and oligonucleotide primers were derived from the 
DNA insertion sequence IS900, which is unique to MAP. The 
primers P90 (Sequence ID 1 inFIG.1) andP91 (Sequence ID 
60 with ulcerative colitis, were newly diagnosed. Patients with 
indeterminate colitis were excluded. Two 4-mL whole blood 
2 in FIG. 2) were used for the first round to amplify a unique 
398 bp fragment of the IS900 gene. The sensitivity and speci- 65 
ficity forthe amplified MAP DNA fragment were achieved by 
use of AV! (Sequence ID 3 in FIG. 3) andAV2 (Sequence ID 
samples drawn into sterile K2-EDTA Vacutainer tubes were 
obtained from every participant. All samples were coded to 
conceal the patient's identity and the diagnosis. The samples 
were immediately processed in a class II biosafety cabinet. 
The buffy coat layer from each tube was transferred into a 
separate sterile tube that was used for either genomic DNA 
US 7,488,580 Bl 
5 
extraction or culture. A medication history was completed for 
each participant as shown in Table 1. Use of prednisone, 
budesonide, azathioprine, mercaptopurine, methotrexate, or 
infliximab at any dose was judged to be immunosuppressive. 
Products containing mesalamine were not considered to be 5 
immunosuppressive. Procedures for culture, each buffy coat 
sample was resuspended in 1 mL of sterile phosphate buffer 
saline, pH 6.8. Samples (0.5 mL) of the suspension were used 
to inoculate one MG IT and one 12B * BACTEC bottle (Beck-
ton Dickinson, Franklin Lake, N.J., USA), each containing 4 10 
mL of modified Middlebrook 7H9 broth base media (Becton 
Dickinson) with supplements as previously described. All 
inoculated culture media were incubated at 37° C. in a 5% 
carbon dioxide incubator. The BACTEC bottles were 
assessed every week with the BACTEC 460TB Analyzer 15 
(Becton Dickinson) and the MGIT were checked every 2 
weeks for visible turbidity and fluorescence-quenching activ-
ity with a 365 nm UV-illuminator. The BACTEC bottles with 
a growth index reading of 50 or more, and all MGIT cultures 
incubated for 8-12 weeks, were assessed for the presence of 20 
MAP by staining and nested PCR. MAP cells were inacti-
vated by heating the cell pellet from a 0-5 mL sample of the 
culture in 500 µL TE buffer (10 mM Tris and 1 mM EDTA, pH 
8.0 HCl) at 80° C. for 10 min. The sample was centrifuged at 
10000 rpm (12800 g) for 5 min and the cell pellet was sus- 25 
pended in 150 µL of sterile water. 50 µL was used to prepare 
smears for Ziehl-Neelsen staining, acridine orange staining, 
or immunostaining with adsorbed rabbit-anti-MAP poly-
clonal IgG antibodies as described previously. The remaining 
volume was used for extraction of genomic DNA for PCR 30 
analysis. 
Analysis of DNA: Genomic DNA was extracted from 
uncultured buffy coat cells and cell culture pellets in a sepa-
rate class II biosafety cabinet. The cells were re-suspended in 
100 µL sterile TE buffer and incubated in a dry heat bath at 35 
100° C. for 30 min, then placed on ice for 15 min. They were 
then centrifuged at 12000 rpm (18500 g) and4° C. for 10 min. 
The supernatant was transferred to 2.0 mL phase-lock gel 
tubes (PLG, Eppendorf, Westbury, N.Y., USA). 200 µl of 
phenol/chloroform/isoamyl alcohol (1: 1:24 v/v; Acros 40 
Organics Morris Plains, N.J., USA) was added, mixed, and 
centrifuged at 12000 rpm (18500 g) and 4 ° C. for 5 min. The 
nucleic acid was precipitated, washed, dried, and dissolved in 
50 µL of sterile water. Both primary and secondary rounds of 
the nested PCR were done in a class II biosafety cabinet used 45 
only for PCR. Oligonucleotide primers were derived from the 
DNA insertion sequence IS900, which is unique to MAP. The 
primers P90 and P91 (Sequence ID 1 in FIG. 1 and Sequence 
ID 2 in FIG. 2, respectively) were used for the first round to 
amplify a unique 398 bp fragment of the IS900 gene. The 50 
sensitivity and specificity for the amplified MAP DNA frag-
ment were achieved by use of AV! and AV2 oligonucleotide 
primers (Sequence ID 3 in FIG. 3 and Sequence ID 4 in FIG. 
4, respectively) in the second round to re-amplify an 298 bp 
internal nucleotide sequence of the 398 bp template. The PCR 55 
reaction mixture consisted of 40 µL PCR buffer: 5-mM 
MgC12, 0.2 mM dNTP, 6% DMSO or 0.5 M Betaine, 2 µM 
primers, and 2.5 U Platinum Taq polymerase (Invitrogen, 
Carlsbad, Calif., USA) or 1 U TFL DNA polymerase 
(Promega, Madison, Wis., USA) and 10 µl of DNA template. 60 
The PCR reaction mixture in the second round of the nested 
PCR was the same, except that 5 µL of PCR product from the 
first round was used as a template and the AV! and AV2 
oligonucleotide primers were substituted. The PCR cycling 
conditions were: 95° C. for 5 min, 34 cycles of 95° C. for 1 65 
min, 58° C. for 1.5 min, 72° C. for 15 min, and a final 
extension of 10 min at 72° C. The amplification product size 
6 
was assessed on 2% agarose gel. Negative controls for PCR 
consisted of sterile TE buffer or sterile water used in place of 
the DNA template, and were used in parallel with every round 
of PCR preparation. Positive MAP DNA from strain ATCC 
43015 was prepared independently and added to PCR tubes at 
a different facility using separate supplies. Nucleotide 
sequencing verified the specificity of the amplified IS900 
fragment. PCR products from the second round of the nested 
PCR from positive samples were purified and sequenced at 
the Biomolecular Science Center DNA Sequencing Core 
facility at the University of Central Florida. BLAST and 
alignment sequence analyses were also done. 
Statistical Analysis: Groups were compared with 2x2 con-
tingency tables and Fishers exact test. A positive (p) value of 
less than 0.05 was judged to be significant. Results: The code 
for concealment of participants' identities and diagnoses was 
broken and data were tabulated after the conclusion of all 
experiments (table 1 ). Participants were aged 18-77 years. 
Overall, 50% were female; 17 ( 61 % ) of those with Crohn' s 
disease, 2 (22%) of those with ulcerative colitis, and 7 ( 4 7%) 
of those without inflammatory bowel disease. 16 ( 62%) of the 
26 patients with Crohn's disease for whom data were avail-
able were known to be on immunosuppressive medications. 
Four ( 44%) patients with ulcerative colitis and none of those 
without inflammatory bowel disease were on such medica-
tions. Samples that were positive for the MAP-specific IS900 
element clearly showed a single bright 298 bp band on 2% 
agarose gel. MAP DNA was detectedin20 of52 (38%) of all 
blood samples (table); 13 (46%) patients with Crohn's dis-
ease, four ( 44%) with ulcerative colitis, and three (20%) 
without inflammatory bowel disease. None of the PCR inter-
nal controls, including one for genomic DNA extraction and 
one in each round of the nested PCR, were positive for MAP 
DNA, indicating no laboratory contamination. Nucleotide 
sequencing of purified MAP DNA fragments from represen-
tative samples that were positive in the second round of the 
nested PCR confirmed the amplification ofIS900 nucleotide 
sequence. After 12 weeks of incubation, possible mycobac-
terial growth was detected in three of 52 BACTEC cultures. 
Detection of possible mycobacterial growth in MGIT cul-
tures inoculated with blood-derived buffy coat based on the 
observation of visible turbidity and increase in fluorescence 
intensity is unreliable. AB 52 MGIT cultures and the three 
BACTEC cultures in which a possible mycobacterial growth 
was detected were assessed for the presence of MAP. IS900-
nested PCR identified MAP in all three suspected BACTEC 
cultures andin 14 of52 MGIT cultures. Only one patient was 
positive for MAP by both culture methods. MAP was isolated 
from culture in 14 (50%) patients with Crohn's disease, two 
(22%) of those with ulcerative colitis, and none of those 
without inflammatory bowel disease (p=0.0005 for group 
with Crohn' s disease vs without inflanimatory bowel disease; 
see FIG. 5). 11 of the 13 patients with Crohn's disease who 
were positive for MAP DNA in blood by PCR were also 
positive by culture, and ten of the 14 subsequently found to be 
positive by culture had also tested positive by PCR. Of the 
four PCR-positive patients with ulcerative colitis, one was 
positive by culture; the other culture-positive ulcerative coli-
tis patient was PCR negative. None of the three PCR-positive 
individuals without inflammatory bowel disease was positive 
by culture. Among the 26 Crohn' s disease patients for whom 
data on the use of immunosuppressive medications were 
available, current use of immunosuppressive medication did 
not correlate with a positive culture result (p=0.23; table). The 
sample size was too small to make any distinction about 
specific immunosuppressive medications, age of onset, dis-
ease duration, or clinical phenotype. MAP-positive cultures 
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tutions (CG instead ofGC located at 114-115 of the 1451 bp 
encoding sequence of the IS900 locus) in seven MAP clinical 
isolates. Only one IS900 locus (accession number X16293) 
showed no CG switching. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ofbuffy coat were negative by acid-fast Ziehl-Neelsen stain-
ing during the early weeks of culture incubation, but were 
positive by acridine orange or immunostaining with rabbit 
anti-MAP IgG polyclonal antibodies as shown in FIG. 6A. 
FIG. 6A is an illustration of a cell-wall-deficient MAP from 
5-week-old MGIT culture from patient with Crohn's disease. 
After 12 weeks of incubation, all 16 MAP-positive cultures 
contained acid fast bacilli, with the occasional presence of 
deformed cells containing renmant cell wall components, 
also known as pre-spheroplasts as shown in FIG. 6B. FIG. 6B 
is a representative acid-fast positive MAP culture from a 
patient with Crohn's disease. 
l O ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 20 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM: mycobacterium Avium 
<400> SEQUENCE, 1 
gttcggggcc gtcgcttagg 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM: mycobacterium Avium 
<400> SEQUENCE, 2 
gaggtcgatc gcccacgtga 
<210> SEQ ID NO 3 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM: mycobacterium Avium 
<400> SEQUENCE, 3 
atgtggttgc tgtgttggat gg 
<210> SEQ ID NO 4 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM: mycobacterium Avium 
<400> SEQUENCE, 4 
ccgccgcaat caactccag 
To investigate the diversity of the MAP isolates, the 298 bp 
was sequenced and amplifed IS900 fragment from 11 repre-
sentative MAP-positive cultures. The nucleotidesequences 55 
were assessed against each other, the sequence from the labo-
ratory MAP strain (positive control), and several IS900 loci 
available in the National Center for Biotechnology Informa-
tion database (http://www.ncbi.nlm.nih.gov). All sequences 
were confirmed as IS900. Nine of the 11 MAP isolates were 60 
different from each other because of nucleotide polymor-
phisms including insertions, deletions, and substitutions. All 
11 MAP isolates differed from the MAP-positive control used 
in our laboratory. Of 11 IS900 loci published in the database, 
ten (accession numbers AF416985, AJ250023, AJ250022, 65 
AJ250015, AJ250016, AJ250017, AJ250018, AJ250019, 
AJ250020, AJ250021) showed two consecutive base substi-
20 
20 
22 
19 
I claim: 
1. A method of diagnosing inflammatory bowel disease in 
those patients who have bowel disease caused by Mycobac-
terium avium subspecies paratuberculosis (MAP) using a 
sample of peripheral blood tissue comprising the steps of: 
selecting a blood sample from at least a single patient of 
selected patients; 
culturing the blood sample for a period of time sufficient to 
obtain a sufficient growthofMAPto subject to PCR; and 
detecting MAP therefrom, said PCR method used to detect 
MAP comprising using one or more of the group con-
sisting of SEQ ID NO: 1, SEQ ID N0:2, SEQ ID N0:3 
and SEQ ID N0:4 as primers for nested PCR, said 
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patients being human patients, and said sample of blood 
consisting of the buffy coat. 
2. The method of claim 1, wherein the human patient has 
inflammatory bowel disease selected from at least one of: 
Crohn's disease, irritable bowel disease (IBD), and ulcerative 5 
colitis. 
3. The method of claim 1 wherein the inflammatory bowel 
disease is Crohn's disease. 
4. The method of claim 1, further comprising treating MAP 
infected patients who have MAP detected in their blood with 10 
an anti-MAP effective amount of an anti-MAP compound 
and a pharmaceutically acceptable excipient therefor. 
5. The method of claim 2, further comprising treating MAP 
infected patients who have MAP detected in their blood with 
an anti-MAP effective amount of an anti-MAP compound 15 
and a pharmaceutically acceptable excipient therefor. 
6. The method of claim 4 wherein said anti-MAP com-
pound comprises an antibiotic. 
7. The method of claim 6, wherein said effective amount is 
an amount sufficient to eliminate MAP from registering posi- 20 
tive in a blood test. 
8. The method of claim 1 wherein the time required to 
culture the blood sample is approximately 8 weeks to 
approximately 12 weeks. 
9. The method of claim 8, wherein the time required to 25 
culture the blood sample is approximately 12 weeks. 
10. The method of claim 1 where the blood sample is 
cultured in media selective for MAP. 
11. The method of claim 1 wherein the media selective for 
MAP is selected from the group consisting ofMycobacterial 30 
Growth Indicator Tube (MGIT) or BACTEC. 
12. The method of claim 11, wherein the MGIT or 
BACTEC is further supplemented with 1 % sucrose. 
10 
13. The method of claim 1 wherein the primers comprise 
one or more of the group consisting of Seq ID 1, Seq ID 2, Seq 
ID 3 and Seq ID 4 and nucleotide polymorphisms thereof. 
14. The method of claim 1 wherein one or more of Seq ID 
1 or Seq ID 2 are used as primers in the first round of PCR and 
one or more of Seq ID 3 or Seq ID 4 were used in the second 
round of PCR. 
15. The method, as in claim 13 wherein one or more of Seq 
ID 1 or Seq ID 2 are used as primers in the first round of PCR 
and one or more of Seq ID 3 or Seq ID 4 are used in the second 
round of PCR. 
16. A method for monitoring and evaluating the course of 
inflammatory bowel disease caused by MAP comprising: 
selecting a blood sample from at least a single patient of 
selected patients; 
culturing the blood sample for a period of time sufficient to 
obtain a sufficient growth of MAP to subject to PCR; 
detecting MAP therefrom; 
obtaining a positive result from MAP; and 
continuing to repeat said test at intervals throughout treat-
ment wherein the method PCR method used to detect 
MAP comprises using one of more of the group consist-
ing of SEQ ID NO: 1, SEQ ID N0:2, SEQ ID N0:3 and 
SEQ ID N0:4 as primers for nested PCR, said patients 
being human patients, and said sample of blood consist-
ing of the buffy coat. 
17. The method, as in claim 16 wherein the inflammatory 
bowel disease is Crohn's disease. 
18. The method, as in claim 1 wherein the volume of blood 
extracted from the patient for use in the test is 4 mis or greater. 
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